Reversible Neurological Adverse Reaction to Apixaban

Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The auth...

Full description

Bibliographic Details
Main Authors: Eduardo Rodrigues Cernadas, Catarina Dionisio, Dalia Estevão, Leopoldina Vicente
Format: Article
Language:English
Published: SMC MEDIA SRL 2021-04-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/1739
id doaj-19cf26e17f864e88a323b0abbebc468c
record_format Article
spelling doaj-19cf26e17f864e88a323b0abbebc468c2021-04-19T16:13:43ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942021-04-0110.12890/2021_0017391371Reversible Neurological Adverse Reaction to ApixabanEduardo Rodrigues Cernadas0Catarina Dionisio1Dalia Estevão2Leopoldina Vicente3Centro Hospitalar Universitário Cova da Beira, Covilhã, PortugalCentro Hospitalar Universitário Cova da Beira, Covilhã, PortugalCentro Hospitalar Universitário Cova da Beira, Covilhã, PortugalCentro Hospitalar Universitário Cova da Beira, Covilhã, PortugalPrescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The authors report the case of an 80-year-old woman followed by her cardiologist for permanent atrial fibrillation who was prescribed apixaban. Within a few days the patient developed neurological symptoms of imbalance and non-vertiginous dizziness, headache, confusion/disorientation and asthenia. Her symptoms began to resolve after the drug was stopped, with return to baseline function within 72 h. The plasma concentration of apixaban was 4 times higher than the laboratory upper limit of normal. Symptoms did not recur when the patient was switched to rivaroxaban therapy.https://www.ejcrim.com/index.php/EJCRIM/article/view/1739apixabanneurological symptomsadverse drug reaction
collection DOAJ
language English
format Article
sources DOAJ
author Eduardo Rodrigues Cernadas
Catarina Dionisio
Dalia Estevão
Leopoldina Vicente
spellingShingle Eduardo Rodrigues Cernadas
Catarina Dionisio
Dalia Estevão
Leopoldina Vicente
Reversible Neurological Adverse Reaction to Apixaban
European Journal of Case Reports in Internal Medicine
apixaban
neurological symptoms
adverse drug reaction
author_facet Eduardo Rodrigues Cernadas
Catarina Dionisio
Dalia Estevão
Leopoldina Vicente
author_sort Eduardo Rodrigues Cernadas
title Reversible Neurological Adverse Reaction to Apixaban
title_short Reversible Neurological Adverse Reaction to Apixaban
title_full Reversible Neurological Adverse Reaction to Apixaban
title_fullStr Reversible Neurological Adverse Reaction to Apixaban
title_full_unstemmed Reversible Neurological Adverse Reaction to Apixaban
title_sort reversible neurological adverse reaction to apixaban
publisher SMC MEDIA SRL
series European Journal of Case Reports in Internal Medicine
issn 2284-2594
publishDate 2021-04-01
description Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The authors report the case of an 80-year-old woman followed by her cardiologist for permanent atrial fibrillation who was prescribed apixaban. Within a few days the patient developed neurological symptoms of imbalance and non-vertiginous dizziness, headache, confusion/disorientation and asthenia. Her symptoms began to resolve after the drug was stopped, with return to baseline function within 72 h. The plasma concentration of apixaban was 4 times higher than the laboratory upper limit of normal. Symptoms did not recur when the patient was switched to rivaroxaban therapy.
topic apixaban
neurological symptoms
adverse drug reaction
url https://www.ejcrim.com/index.php/EJCRIM/article/view/1739
work_keys_str_mv AT eduardorodriguescernadas reversibleneurologicaladversereactiontoapixaban
AT catarinadionisio reversibleneurologicaladversereactiontoapixaban
AT daliaestevao reversibleneurologicaladversereactiontoapixaban
AT leopoldinavicente reversibleneurologicaladversereactiontoapixaban
_version_ 1721519143878918144